Inclusion criteria:

        All parts

          -  Previously-identified activating Kirsten rat sarcoma viral oncogene homologue (KRAS)
             mutation in tumour tissue or blood prior to screening

          -  At least one target lesion that can be measured per Response Evaluation Criteria In
             Solid Tumours (RECIST) version 1.1.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Adequate organ function

          -  Age ≥18 years of age, or over the legal age of consent as required by local
             legislation.

          -  Signed and dated written informed consent in accordance with GCP and local legislation
             prior to admission to the trial.

          -  Women of childbearing potential who are not surgically sterilized must have a negative
             serum pregnancy test completed during the Screening period

          -  Further inclusion criteria apply

        Monotherapy and combination therapy dose escalation and monotherapy dose confirmation part

        - Documented disease progression despite appropriate prior standard therapies or for whom
        no standard therapy exists for their tumour type and disease stage

        Combination dose confirmation and expansion cohort

          -  Pathologically confirmed diagnosis of adenocarcinoma of the lung. Patients with mixed
             histology are eligible if adenocarcinoma is the predominant histology.

          -  Locally advanced stage IIIb or metastatic stage IV Non-small cell lung cancer (NSCLC)

          -  Patients must have received both chemotherapy and immunotherapy

        Exclusion criteria:

        All parts

          -  Previous anticancer chemotherapy within 3 weeks of the first administration of trial
             drug.

          -  Previous treatment with RAS, Mitogen-activated protein kinase (MAPK) or Son of
             sevenless 1 (SOS1) targeting agents

          -  Major surgery performed within 4 weeks prior to start of treatment

          -  Uncontrolled hypertension, congestive heart failure NYHA classification of ≥3,
             unstable angina or poorly controlled arrhythmia. Myocardial infarction within 6 months
             prior to start of treatment

          -  Left ventricular ejection fraction (LVEF) <50 %

          -  Congenital long QT prolongation syndrome

          -  Mean resting corrected QT interval (QTcF) >470 msec

          -  Leptomeningeal carcinomatosis

          -  Presence or history of uncontrolled or symptomatic brain metastases

          -  Known pre-existing interstitial lung disease

          -  Known active hepatitis B infection (defined as presence of Hep B sAg and/or Hep B
             Deoxyribonucleic acid (DNA)), active hepatitis C infection (defined as presence of Hep
             C Ribonucleic acid (RNA))

          -  Active infectious disease

          -  Any history or presence of uncontrolled gastrointestinal disorders that could affect
             the intake and/or absorption of the trial drug

          -  History of retinal vein occlusion (RVO) or retinal pigment epithelial detachment
             (RPED)

          -  Further exclusion criteria apply

        Combination part

        - Hypersensitivity to any of the excipients listed in the current Summary of Product
        Characteristics (SmPC)/Package insert (PI) of trametinib